[go: up one dir, main page]

MA67365B1 - Dérivés de benzisoxazole sulfonamide - Google Patents

Dérivés de benzisoxazole sulfonamide

Info

Publication number
MA67365B1
MA67365B1 MA67365A MA67365A MA67365B1 MA 67365 B1 MA67365 B1 MA 67365B1 MA 67365 A MA67365 A MA 67365A MA 67365 A MA67365 A MA 67365A MA 67365 B1 MA67365 B1 MA 67365B1
Authority
MA
Morocco
Prior art keywords
sup
compounds
derivatives
benzisoxazole
sulfonaminate
Prior art date
Application number
MA67365A
Other languages
English (en)
Inventor
Robert Arnold Kumpf
Pei-Pei Kung
Scott Channing Sutton
Samantha Elizabeth GREASLEY
Robert Louis Hoffman
Paul Francis Richardson
Ylva Elisabet Bergman BOZIKIS
Oleg Brodsky
Michelle Ang CAMERINO
Paul Anthony Stupple
Original Assignee
Pfizer Inc.
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Ctxt Pty Ltd filed Critical Pfizer Inc.
Publication of MA67365B1 publication Critical patent/MA67365B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, dans lesquels le cycle A, R<sup>1</sup>-R<sup>8</sup> et n sont définis ici. Les nouveaux dérivés de sulfonamide de benzisoxazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les patients. Des modes de réalisation supplémentaires concernent des compositions pharmaceutiques contenant les composés et des procédés d'utilisation des composés et des compositions dans le traitement de la croissance cellulaire anormale chez les patients.
MA67365A 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide MA67365B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
EP23203023.9A EP4299135B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Publications (1)

Publication Number Publication Date
MA67365B1 true MA67365B1 (fr) 2025-10-31

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67365A MA67365B1 (fr) 2019-06-18 2020-06-16 Dérivés de benzisoxazole sulfonamide

Country Status (33)

Country Link
US (2) US11492346B2 (fr)
EP (2) EP3986890B9 (fr)
JP (2) JP7352662B2 (fr)
KR (1) KR102823056B1 (fr)
CN (1) CN114364672B (fr)
AU (2) AU2020296361A1 (fr)
BR (1) BR112021025528A2 (fr)
CA (1) CA3143666C (fr)
CL (1) CL2021003372A1 (fr)
CO (1) CO2021017504A2 (fr)
CR (1) CR20210627A (fr)
DK (2) DK4299135T3 (fr)
EC (1) ECSP21091615A (fr)
ES (2) ES2969616T3 (fr)
FI (2) FI3986890T3 (fr)
HR (2) HRP20251225T1 (fr)
HU (1) HUE064683T2 (fr)
IL (1) IL288802B2 (fr)
LT (2) LT3986890T (fr)
MA (1) MA67365B1 (fr)
MD (2) MD3986890T3 (fr)
MX (1) MX2021016085A (fr)
MY (1) MY210207A (fr)
PE (1) PE20220808A1 (fr)
PH (1) PH12021553107A1 (fr)
PL (2) PL4299135T3 (fr)
PT (2) PT3986890T (fr)
RS (2) RS67276B1 (fr)
SI (1) SI3986890T1 (fr)
TW (1) TWI787620B (fr)
UA (1) UA129891C2 (fr)
UY (1) UY38752A (fr)
WO (1) WO2020254946A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
BR112023000687A2 (pt) * 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
WO2022187688A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison de kras covalents à des fins thérapeutiques
WO2022187693A1 (fr) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Composés de liaison à cdk2 covalents utilisés à des fins thérapeutiques
MX2023013683A (es) * 2021-05-21 2024-02-23 Aurigene Oncology Ltd Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
WO2023280182A1 (fr) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 Composé servant d'inhibiteur de kat6
KR20240046530A (ko) 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
AU2022390319A1 (en) * 2021-11-16 2024-05-30 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
EP4448109A1 (fr) * 2021-12-13 2024-10-23 Aurigene Oncology Limited Composés benzoisoxazolyle fusionnés en tant qu'inhibiteurs de kat6a
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
CN119301096A (zh) 2022-03-28 2025-01-10 伊索斯泰里克斯公司 Myst家族赖氨酸乙酰转移酶的抑制剂
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (fr) 2022-07-29 2024-02-01 Pfizer Inc. Schémas posologiques comprenant un inhibiteur de kat6 pour le traitement du cancer
CN120476113A (zh) * 2022-12-20 2025-08-12 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
AU2024217108A1 (en) 2023-02-10 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfonamide derivative and preparation method therefor
WO2024189598A2 (fr) 2023-03-16 2024-09-19 Olema Pharmaceuticals, Inc. Inhibiteurs de kat6a de type acylsulfonamides
KR20250157556A (ko) * 2023-03-27 2025-11-04 베이징 콘런스 파마슈티칼 컴퍼니 리미티드 설폰아미드 화합물, 이의 약학적 조성물과 응용
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
AU2024259385A1 (en) * 2023-04-19 2025-12-04 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof
WO2024222725A1 (fr) * 2023-04-25 2024-10-31 Insilico Medicine Ip Limited Inhibiteur de lysine acétyltransférase 6a (kat6a) cristallin et ses utilisations
TW202504580A (zh) * 2023-07-04 2025-02-01 大陸商上海齊魯製藥研究中心有限公司 Kat6抑制劑
WO2025036382A1 (fr) * 2023-08-14 2025-02-20 上海复宏汉霖生物医药有限公司 Composé sulfonamide, son procédé de préparation et son utilisation
TW202530223A (zh) * 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025098417A1 (fr) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 Composé sulfonamide et son utilisation
WO2025141469A1 (fr) 2023-12-26 2025-07-03 Pfizer Inc. Forme cristalline de 2-méthoxy-n-4-méthoxy-6-[(1h-pyrazol-1-yl)méthyl]-1,2-benzoxazol-3-yl}benzène-1-sulfonamide

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (fr) 1970-10-08 1974-02-25
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ231534A (en) 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
JP2902834B2 (ja) 1991-10-09 1999-06-07 本田技研工業株式会社 自己伸縮型マウント
TW224462B (fr) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0626174A3 (fr) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Procédé et composition de prophylaxie et/ou traitement de la hypofonction d'organes.
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
EP1048657A1 (fr) 1995-04-04 2000-11-02 Texas Biotechnology Corporation Thiényl-, furyl-, pyrrolyl- et biphénylsulfonamides et dérivés de ceux-ci modulant l'activité d'endothéline
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
EP0938477A4 (fr) 1996-11-13 1999-12-29 Cephalon Inc Inhibiteurs benzothiazo, ou contenant des groupes heterocycliques apparentes, de la cysteine ou des proteases serines
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001049289A1 (fr) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Utilisations pharmaceutiques et veterinaires d'antagonistes de l'endotheline et applications associees
CA2401778C (fr) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides et inhibiteurs associes du facteur xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
PL370447A1 (en) 2001-11-22 2005-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1631558A1 (fr) 2003-05-21 2006-03-08 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy steroide deshydrogenase de type i
WO2004113310A1 (fr) 2003-06-25 2004-12-29 Biovitrum Ab Utilisation d'un inhibiteur de compose de type 1 11-b-hydroxysteroide deshydrogenase type 1 destine a faciliter la cicatrisation d'une plaie
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
WO2005049593A2 (fr) 2003-11-13 2005-06-02 Abbott Laboratories Promoteurs de l'apoptose contenant n-acylsulfonamide
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
RU2407736C2 (ru) 2004-10-12 2010-12-27 Декод Дженетикс Ехф Пери-замещенные арилсульфонамидные бициклические соединения, предназначенные для лечения окклюзионного заболевания артерий
DE602006012650D1 (de) 2005-04-26 2010-04-15 Hypnion Inc Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
WO2006116615A1 (fr) 2005-04-26 2006-11-02 Hypnion, Inc. Composes de benzisoxazole piperazine et procedes pour leur utilisation
US7745629B2 (en) 2005-05-16 2010-06-29 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
CN101282969A (zh) 2005-10-06 2008-10-08 塞诺菲-安万特股份有限公司 双环芳基-磺酸[1,3,4]-噻二唑-2-基-酰胺、它们的制备方法以及它们作为药物的用途
JP2009510147A (ja) 2005-10-06 2009-03-12 サノフィ−アベンティス Ｎ−［１，３，４］−チアジアゾール−２−イル−ベンゼンスルホンアミド類、それらの製造方法及び医薬品としてのそれらの使用
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
WO2007075895A2 (fr) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Derives heterocycliques utilises comme modulateurs de canaux ioniques
EP2054056A4 (fr) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa Petits inhibiteurs moleculaires de la kynurenine-3- monooxygenase
WO2008064116A2 (fr) 2006-11-16 2008-05-29 Abbott Laboratories Procédé pour éviter ou traiter les rejets lors de transplantations d'organes, de cellules souches hématopoïétiques ou de moelle osseuse
AU2007321921A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2008089307A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
AU2008319267A1 (en) 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
CA2709784A1 (fr) 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
MX2010006647A (es) 2007-12-26 2010-08-17 Sanofi Aventis Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
JP5774989B2 (ja) 2008-08-13 2015-09-09 スメド−ティーエイ／ティーディー・エルエルシー 整形外科用ねじ
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
EP2421833B1 (fr) 2009-04-21 2015-01-14 Nerviano Medical Sciences S.r.l. Dérivés de resorcinol comme inhibiteurs de hsp90
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
PT2471786E (pt) 2009-08-07 2016-03-04 Hoffmann La Roche Derivado de aminopirazol
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (fr) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 Composés de formanilide hétérocyclique, leurs procédés de synthèse et leur utilisation
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012080729A2 (fr) 2010-12-14 2012-06-21 Electrophoretics Limited Inhibiteurs de caséine kinase 1δ (ck1δ)
EP2655334B1 (fr) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utilisables en vue du traitement de maladies
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
EP2970156B1 (fr) 2013-03-15 2018-07-25 Genentech, Inc. Benzoxazoles substitués et leurs procédés d'utilisation
WO2015102929A1 (fr) 2013-12-30 2015-07-09 Novartis Ag Dérivés de sulfonamide tricycliques
EP3097101B1 (fr) 2014-01-24 2020-12-23 Merck Sharp & Dohme Corp. Dérivés d'isoquinoline utilisés comme inhibiteurs de mgat2
KR102458990B1 (ko) 2014-04-23 2022-10-25 미쓰비시 타나베 파마 코퍼레이션 신규한 바이시클릭 또는 트리시클릭 헤테로시클릭 화합물
JP5900759B2 (ja) 2014-09-25 2016-04-06 Toto株式会社 小便器
KR20170119705A (ko) 2015-02-24 2017-10-27 화이자 인코포레이티드 항암제로서 유용한 치환된 뉴클레오시드 유도체
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (fr) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Inhibiteurs sélectifs de cellules sénescentes et leurs utilisations
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3548480A1 (fr) * 2016-11-29 2019-10-09 Epizyme, Inc. Composés contenant un groupe sulfonique en tant qu'inhibiteurs de kat
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia

Also Published As

Publication number Publication date
PL4299135T3 (pl) 2025-11-12
ECSP21091615A (es) 2022-01-31
EP3986890B1 (fr) 2023-11-15
EP3986890B9 (fr) 2025-04-16
WO2020254946A1 (fr) 2020-12-24
RS67276B1 (sr) 2025-10-31
LT4299135T (lt) 2025-09-10
HRP20251225T1 (hr) 2025-12-05
CR20210627A (es) 2022-02-08
US12371425B2 (en) 2025-07-29
FI3986890T3 (fi) 2024-01-15
RS64931B9 (sr) 2025-06-30
RS64931B1 (sr) 2023-12-29
JP2023175821A (ja) 2023-12-12
CA3143666A1 (fr) 2020-12-24
DK3986890T3 (da) 2023-12-18
MD4299135T2 (ro) 2025-11-30
CL2021003372A1 (es) 2022-10-07
PH12021553107A1 (en) 2022-08-01
PE20220808A1 (es) 2022-05-20
EP4299135A3 (fr) 2024-02-28
MY210207A (en) 2025-09-03
HUE064683T2 (hu) 2024-04-28
TWI787620B (zh) 2022-12-21
CN114364672A (zh) 2022-04-15
US20200399258A1 (en) 2020-12-24
PT4299135T (pt) 2025-10-09
LT3986890T (lt) 2023-12-11
CN114364672B (zh) 2024-09-06
HRP20231501T1 (hr) 2024-03-01
FI4299135T3 (fi) 2025-10-01
ES3043899T3 (en) 2025-11-26
IL288802A (en) 2022-02-01
DK4299135T3 (da) 2025-09-08
TW202115048A (zh) 2021-04-16
MD3986890T2 (ro) 2024-04-30
CA3143666C (fr) 2024-06-11
SI3986890T1 (sl) 2024-03-29
MD3986890T3 (ro) 2025-07-31
ES2969616T3 (es) 2024-05-21
EP3986890A1 (fr) 2022-04-27
AU2020296361A1 (en) 2022-01-06
CO2021017504A2 (es) 2022-01-17
IL288802B2 (en) 2025-08-01
MX2021016085A (es) 2022-04-20
PL3986890T3 (pl) 2024-03-11
IL288802B1 (en) 2025-04-01
UY38752A (es) 2021-01-29
UA129891C2 (uk) 2025-09-03
KR102823056B1 (ko) 2025-06-23
AU2023274178A1 (en) 2024-02-15
BR112021025528A2 (pt) 2022-04-19
US11492346B2 (en) 2022-11-08
KR20220024671A (ko) 2022-03-03
EP4299135A2 (fr) 2024-01-03
EP4299135B1 (fr) 2025-08-06
JP2022537285A (ja) 2022-08-25
US20230174522A1 (en) 2023-06-08
PT3986890T (pt) 2024-01-17
JP7352662B2 (ja) 2023-09-28

Similar Documents

Publication Publication Date Title
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
TN2009000544A1 (fr) Derives de benzimidazole
MA30403B1 (fr) Derives d&#39;acides cycloalkylamines et leurs compositions pharmaceutiques
MA54327B1 (fr) Inhibiteurs de kras g12c
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu&#39;inhibiteurs de kinases dépendantes des cyclines
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d&#39;une croissance cellulaire anormale
MA29926B1 (fr) Derives de pyrazine
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA31754B1 (fr) Cis-imidazolines chirales
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31894B1 (fr) Composes organiques
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
TR200003383T2 (tr) HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler.
MA57000B1 (fr) Dérivés d&#39;alpha-d-galactopyranoside